Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Receives $71.40 Consensus Price Target from Brokerages

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has been given an average rating of “Buy” by the thirteen ratings firms that are currently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $71.60.

Several equities research analysts have weighed in on the stock. Barclays restated a “hold” rating and issued a $55.00 target price on shares of Biohaven Pharmaceutical in a research note on Friday, May 31st. Zacks Investment Research downgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, July 19th. ValuEngine cut shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a report on Wednesday, June 19th. Goldman Sachs Group set a $89.00 price objective on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a report on Wednesday. Finally, Oppenheimer set a $68.00 target price on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, June 19th.

In other news, Director John W. Childs purchased 10,000 shares of the stock in a transaction dated Wednesday, June 26th. The stock was acquired at an average cost of $40.37 per share, for a total transaction of $403,700.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Vlad Coric bought 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 26th. The stock was bought at an average cost of $40.22 per share, for a total transaction of $201,100.00. The disclosure for this purchase can be found here. Insiders bought a total of 22,500 shares of company stock valued at $900,675 in the last quarter. Insiders own 23.90% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Manchester Capital Management LLC acquired a new stake in shares of Biohaven Pharmaceutical in the first quarter worth approximately $52,000. Tower Research Capital LLC TRC acquired a new stake in shares of Biohaven Pharmaceutical in the second quarter worth approximately $65,000. Aperio Group LLC acquired a new stake in shares of Biohaven Pharmaceutical in the second quarter worth approximately $71,000. Glen Harbor Capital Management LLC boosted its position in shares of Biohaven Pharmaceutical by 165.9% in the second quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock worth $76,000 after acquiring an additional 1,088 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Biohaven Pharmaceutical by 94.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,256 shares of the company’s stock worth $99,000 after acquiring an additional 1,097 shares during the last quarter. 72.33% of the stock is currently owned by institutional investors and hedge funds.

Biohaven Pharmaceutical stock traded up $0.59 during midday trading on Thursday, reaching $41.49. The stock had a trading volume of 561,501 shares, compared to its average volume of 588,713. Biohaven Pharmaceutical has a 52-week low of $29.17 and a 52-week high of $67.86. The company has a fifty day moving average of $40.46 and a 200 day moving average of $49.77.

Biohaven Pharmaceutical (NYSE:BHVN) last issued its earnings results on Thursday, August 8th. The company reported ($2.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.09) by ($0.26). Research analysts anticipate that Biohaven Pharmaceutical will post -7.51 earnings per share for the current fiscal year.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Further Reading: Asset Allocation Models, Which is Right For You?

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit